Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 October 2017Website:
http://rhythmtx.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 21:38:47 GMTDividend
Analysts recommendations
Institutional Ownership
RYTM Latest News
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology .
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee - Executive Vice President and Head of North America Yann Mazabraud - Executive Vice President and Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Corinne Johnson - Goldman Sachs Group, Inc. Seamus Fernandez - Guggenheim Securities Dae Gon Ha - Stifel, Nicolaus & Company, Inc. Whitney Ijem - Canaccord Genuity Corp. Jeff Hung - Morgan Stanley Tazeen Ahmad - Bank of America Merrill Lynch Joseph Stringer - Needham & Company Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.76 per share a year ago.
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on October 4, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 30,050 shares of its common stock to nine new employees.
IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. The company is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months.
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,450 shares of its common stock to four new employees.
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 --
- 1(current)
What type of business is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic agents for the treatment of rare genetic disorders characterized by severe obesity and unrelenting hunger or hyperphagia. The company was founded in 2013 in Boston, Massachusetts. The company's research is dedicated to studying rare genetic obesity disorders caused by a disruption in the pathway in the brain known as the melanocortin-4 receptor (MC4R) pathway. The company produces an MC4R agonist - setmelanotide, the use of which may serve as a replacement therapy for the treatment of MC4R pathway deficiency. The company also has a number of drugs in early stages of research. Currently, the company does not have any approved drugs.
What sector is Rhythm Pharmaceuticals in?
Rhythm Pharmaceuticals is in the Healthcare sector
What industry is Rhythm Pharmaceuticals in?
Rhythm Pharmaceuticals is in the Biotechnology industry
What country is Rhythm Pharmaceuticals from?
Rhythm Pharmaceuticals is headquartered in United States
When did Rhythm Pharmaceuticals go public?
Rhythm Pharmaceuticals initial public offering (IPO) was on 09 October 2017
What is Rhythm Pharmaceuticals website?
https://rhythmtx.com
Is Rhythm Pharmaceuticals in the S&P 500?
No, Rhythm Pharmaceuticals is not included in the S&P 500 index
Is Rhythm Pharmaceuticals in the NASDAQ 100?
No, Rhythm Pharmaceuticals is not included in the NASDAQ 100 index
Is Rhythm Pharmaceuticals in the Dow Jones?
No, Rhythm Pharmaceuticals is not included in the Dow Jones index
When was Rhythm Pharmaceuticals the previous earnings report?
No data
When does Rhythm Pharmaceuticals earnings report?
The next expected earnings date for Rhythm Pharmaceuticals is 21 February 2025